Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

	Order the Paperwork Reducator Act of 1990; no persons are required to respond to a conection of information diffess it contains a valid Owle control flumber.							
Sub	estitute for form 1449/PTO			Complete if Known				
				Application Number	09/501,102-Conf. #3404			
IN.	IFORMATION	I DI	SCLOSURE	Filing Date	February 9, 2000			
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Beatriz M. Carreno			
				Art Unit	1644			
	(Use as many she	eets as	necessary)	Examiner Name	P. Gambel			
Sheet	1	of	3	Attorney Docket Number	WYS-004.01			

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	AA*	US-5,397,703	03-14-1995	De Boer et al.					
	AB*	US-5,562,903	10-08-1996	Co et al.					
	AC*	US-5,622,701	04-22-1997	Berg					
	AD*	US-5,869,050	02-09-1999	de Boer et al.					
	AE*	US-5,919,449	07-06-1999	Dinsmore					
	AF*	US-5,977,318	11-02-1999	Linsley et al.					
	AG*	US-6,084,067	07-04-2000	Freeman et al.					
	AH*	US-6,096,537	08-01-2000	Chappel					
	Al*	US-6,130,316	10-10-2000	Freeman et al.					
	AJ*	US-6,346,248	02-12-2002	De Boer et al.					
	AK*	US-6,608,180-A1	08-19-2003	Sharpe et al.					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
	BA	WO 94/01547	01-20-1994			г			
	BB	WO 95/34320	12/1995			Г			
	BC	WO 98/19706	05-14-1998			г			
	BD	WO 00/19706	04-06-2000			г			

**EXAMINED: Initial if afference consistents, whether or not clusted in a conformance with MIFE 980. Date fine through distant find in conformance and not considered. Include copy of this form with new documentational to applicant. **CITE NOS. These applicationary which were marked with an engine statering who to the Cite No. see not supplied (under 37 CFR 1.98(s)(2)(iii)) because that application was filled after June 30, 2003 or a evaluable in the FW. **Applicant's improvement and provided after June 30, 2003 or a evaluable in the FW. **Applicant's improvement and provided after June 30, 2003 or a evaluable in the FW. **Applicant of the Comment of the Commentation of the Comm

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	CA	Azurna et al., "B70 antigen is a second ligand for CTLA-2 and CD28," Nature, 366:76-79 (1993)					
	СВ	Berzofsky et al., "Antigen-Antibody Interation," In Fundamental Immunology, W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984)	Г				
	СС	Bluestone, J.A., "Costimulation and its role in organ transplantation," Clinical Transplantation, 10:104-109 (1996)	Г				
	CD	Chen et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992)	Г				
	CE	Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," The J. of Immunology, 148(4):1149-1154 (1992)					
	CF	Cromwell et al., Abstract: "The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation," Experimental Biology 98 Meeting, April 22, 1998					

Examiner	Date	
Signature	Considered	

PTO:SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number							
Sut	estitute for form 1449/PTO			Complete if Known				
				Application Number	09/501,102-Conf. #3404			
l IN	IFORMATION	I DI	SCLOSURE	Filing Date	February 9, 2000			
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Beatriz M. Carreno			
				Art Unit	1644			
	(Use as many she	eets a	s necessary)	Examiner Name	P. Gambel			
Sheet	2	of	3	Attorney Docket Number	WYS-004.01			

CG	Daikh et al., "The CD28-B7 costimulatory pathway and its role in autoimmune disease," J. of Leukocyte Biol., 62:156-162 (1997)	
СН	Damico et al., "Pharmacokinetics of IV Adminstered Murine Anti-Human B7.1 and Murine Anti- Human B7.2 in Cynomoglus Monkeys," Abstract, 17th Annual Scientific Meeting, January 9, 1998	
CI	Engel et al., "The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes is the CD86 Differentiation antigen," Blood, 84(5):1402-1407 (1994)	
CJ	Fleischer et al., "Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes," Immunology, 89:592-598 (1996)	
СК	Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996)	
CL	Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992)	
СМ	Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perfusion technique," Transplant Immunology, 2:27-34 (1994)	
CN	Harlow and Lane (Eds) Antibodies: A Laboratory Manual, Coldspring Harbor Laboratory 1988, pp. 23-35.	
со	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993)	
CP	Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613- 15619 (1997)	
cq	Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126	
CR	Levitt, M., "Molecular Dynamics of Native Protein," J. Mol. Biol., 168:595-620 (1983)	
cs	Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810	\neg
СТ	Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)	
cu	Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)	
CV	NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GO121042 (July 21, 1986)	
cw	Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)	
сх	Reiser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)	
CY	Rugtveti et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disese (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)	
CZ	Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999(
CA1	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)	
CB1	Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7- Transfected Melanoma Cells," Science, 259:368-369 (1993)	

Examiner	Date	
Signature	Considered	

PTC/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ed to respond to a collection of information unless it contains a valid OMB control number.

Sut	estitute for form 1449/PTO			Complete if Known		
				Application Number	09/501,102-Conf. #3404	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	February 9, 2000	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Beatriz M. Carreno	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	P. Gambel	
Sheet	3	of	3	Attorney Docket Number	WYS-004.01	

CC1 Yokozeki et al., "Functional CD86 (B7-B70) on Cultured Human Langerhans Cells,"	The
Society for Investigative Dermatology, Inc., 106:147-153 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered	